tjpls

Tropical Journal of Pharmaceutical and Life Sciences

Trop. j. pharm. life sci.

Jadoun Science Publishing Group India

IN https://jadounscience.com

2349-9818

342

Review Article

Dapagliflozin and Urinary Tract Infection Risk in Type 2 Diabetes: A Comprehensive Critical Review of Mechanistic, Randomized, and Real-World Evidence

Jenny Sandal Maisangala

Jennyroy304@gmail.com

Department of Pharmacy Practice

Mugdha Vikasita Gannavaram

mugdha.vikasita4@gmail.com

Akhila Mudavath

akkhiakhila31@gmail.com

Department of Pharmacy Practice

Kovidha Ankem

ankemkovidha@gmail.com

Department of Pharmacy Practice

Vattikutti Uma Maheshwara Rao

rao010706@gmail.com

Professor, Department of Pharmcognosy

Department of Pharmacy Practice, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad 501401, Telangana, India CMR College of Pharmacy Department of Pharmacognosy, CMR College of Pharmacy, Kandlokoya, Medchal, Hyderabad 501401, Telangana, India

28 10 2026

Received: 27102026

2026

Jenny Sandal Maisangala, Mugdha Vikasita Gannavaram, Akhila Mudavath, Ankem Kovidha, Dr. Vattikutti uma Maheshwara Rao

<a rel="license" href="https://creativecommons.org/licenses/by-nc/4.0/"><img alt="Creative Commons License" src="//i.creativecommons.org/l/by-nc/4.0/88x31.png" /></a><p>This work is licensed under a <a rel="license" href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial 4.0 International License</a>.</p>

Dapagliflozin Drug safety Glycosuria SGLT2 inhibitors Type 2 diabetes mellitus Urinary tract infection

1. Farxiga (dapagliflozin) tablets: US prescribing information [Internet]. DailyMed; updated 2026 Jul [cited 2026 Oct 25]. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91373924-66dc-4277-aaf2-8536e81a0e4d

2. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

4. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]. Silver Spring (MD): FDA; 2015 Dec 4 [cited 2026 Oct 25]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm

5. Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, et al. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. CMAJ Open. 2018;6(4):E594–602. doi:10.9778/cmajo.20180111

6. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373–81. doi:10.1016/j.diabres.2013.12.052

7. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204–21. doi:10.1002/dmrr.2479

8. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348–55.

9. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503–14. doi:10.1007/s00592-018-1116-0

10. Zheng Z, He D, Chen J, et al. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43:209–25. doi:10.1007/s40261-023-01256-9

11. Viswanathan V, Singh KP. Use of dapagliflozin in the management of type 2 diabetes mellitus: a real-world evidence study in Indian patients (FOREFRONT). Diabetes Technol Ther. 2019;21:415–22. doi:10.1089/dia.2019.0052

12. Ferwani P, Maldar A, Shah N, Chauhan P, Chadha M. Prevalence of bacterial urinary tract infection among patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors: a prospective real-world setting study. J ASEAN Fed Endocr Soc. 2022;37(2):5–8. doi:10.15605/jafes.037.02.04

13. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–6.

14. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AI. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care. 2002;25(8):1405–9.

15. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–41.

16. Xiu F, Stanojcic M, Diao L, Jeschke MG. Stress hyperglycemia, insulin treatment, and innate immune cells. Int J Endocrinol. 2014;2014:486403.

17. Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020;22(8):1357–68. doi:10.1111/dom.14041

18. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27(5):473–8. doi:10.1016/j.jdiacomp.2013.05.004

19. Arshad M, et al. Genito-urinary infection and urinary tract infection in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors: evidence from a systematic literature review of landmark randomized clinical trials. Drug Res (Stuttg). 2024;74(7):307–13. doi:10.1055/a-2347-9824

20. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31 (supplementary table 3).

21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

22. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

23. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–56. doi:10.7326/M18-3136

24. Fisher A, Fralick M, Filion KB, Dell’Aniello S, Douros A, Tremblay É, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for urosepsis: a multi-site prevalent new-user cohort study. Diabetes Obes Metab. 2020;22(9):1648–58. doi:10.1111/dom.14082

25. Aboukaoud M, Morhi Y, Osher E. Sodium-glucose co-transporter 2 inhibitors and severe urinary tract infections: real-world meta-analysis of cohort studies. Ann Pharmacother. 2025;59(10):891–903. doi:10.1177/10600280241312432

26. Yavuz D, Çinpolat HY, Demir AK, Kadı N, Kal Ö, Şahin İ, et al. Use of SGLT2 inhibitors in patients with chronic kidney disease and urinary tract infection: is there a need for concern? J Clin Med. 2025;14(20):7302. doi:10.3390/jcm14207302

27. Wiegley N, So PN. Sodium-glucose cotransporter 2 inhibitors and urinary tract infection: is there room for real concern? Kidney360. 2022;3(11):1991–3. doi:10.34067/KID.0005722022

28. Wangnoo SK, Bhadada SK, Farishta F, Jayaram Naidu GG, Pattnaik I, Manohar KN, et al. Safety and efficacy of fixed-dose combination of dapagliflozin and saxagliptin in patients with type 2 diabetes mellitus – a phase 4 study in India. Front Endocrinol (Lausanne). 2025;16:1528801. doi:10.3389/fendo.2025.1528801

29. Zhou X, Ye X, Guo X, Liu D, Xu J, Hu F, et al. Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol. 2021;12:766125. doi:10.3389/fphar.2021.766125

30. Dong Y, Wang Y, Lan X, Zeng H. A study on the pharmacovigilance of various SGLT-2 inhibitors. Front Med (Lausanne). 2024;11:1515847. doi:10.3389/fmed.2024.1515847

31. Shen J, Yang J, Zhao B. A survey of the FDA’s Adverse Event Reporting System database concerning urogenital tract infections and sodium glucose cotransporter-2 inhibitor use. Diabetes Ther. 2019;10:1043–50. PMID: 30953300.

32. Gorgojo-Martínez JJ, Górriz JL, Cebrián-Cuenca A, Castro Conde A, Velasco Arribas M. Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: a multidisciplinary expert consensus. J Clin Med. 2024;13(21):6509. doi:10.3390/jcm13216509

33. Roddick AJ, Wonnacott A, Webb D, et al; UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease Working Group. UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease, 2023 update. BMC Nephrol. 2023;24:310. doi:10.1186/s12882-023-03339-3

34. Matteucci A, Di Fusco SA, Bonanni M, Castello L, Aquilani S, Fedele S, et al. Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. Daru. 2026;34(2). doi:10.1007/s40199-026-00637-7.

35. Singh NK, Singh AK, Gupta A, Phatak SR, Sharma AK, Patni B, et al. Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in India. BMC Endocr Disord. 2026;26:204. doi:10.1186/s12902-026-02304-z.